The Biktarvy patent settlement you cited can be considered a lower bound for the economics of a potential settlement of ENTA’s patent suit against PFE with respect to Paxlovid, IMO.
Regarding the merits of the two cases, I don’t have an educated opinion on how they compare.
News 
Market Data 
Discover 
